Dr. Lyn Guenther
At the 3rd International Congress on Psoriasis meeting in Paris July 1-3, 2010 and the Canadian Dermatology Association’s 85th Annual Conference June 30-July 4, 2010 in St. John’s Newfoundland, Dr. Guenther presented a poster on infection rates in ustekinumab-treated psoriasis patients with up to 3 years of follow-up.
Ustekinumab is an approved injectable biologic agent used to treat moderate to severe psoriasis. Dr. Guenther has participated as an investigator in a number of clinical trials involving this compound.
The rates of infection remained stable and did not increase with increased exposure to ustekinumab. The rates of serious infections were similar to expected rates for patients with psoriasis treated with systemic agents.